As per the American Cancer Society estimates, the number of cancer cases
in the United States is estimated to have stood at 1,658,370 in 2015. With
growing incidence rate of cancer in the country, the demand for cancer
biomarker for better diagnosis is also increasing at a robust pace. In the US, growing consumption of alcohol and high smoking prevalence
coupled with poor dietary habits and sedentary lifestyle of the citizens is increasing
cancer risk among the country’s population. Moreover, increasing government
funding for cancer biomarker research, coupled with growing use of biomarkers
in drug discovery development and clinical trials is further anticipated to
fuel cancer biomarker market in the US over the next five years.
“United States Cancer Biomarker Market
Opportunities, 2011 - 2021” report
studies the market size and share of various segments and sub-segments of the cancer biomarker market in the United States during
the period 2011 - 2021. In the study, the market has been categorized
into five broader segments that include Immunoassay, Omics Technology,
Cytogenetic Technology, Imaging Technology and Bioinformatics.
The market dynamics section of the report
elaborates the factors that are driving the market as well as the challenges
inhibiting growth. The research study also includes insights of the key market
trends, a detailed analysis of the changing competitive landscape, and revenue
forecasts for each segment and sub-segment.
this information is provided to assist the established market players and new
entrants in taking their strategic decisions, thereby aiding them in
strengthening their market position in a highly competitive cancer biomarker market
in the United States.
States Cancer Biomarker Market Opportunities, 2011 - 2021” report
elaborates the following aspects of cancer
biomarker market in the United States:
ü United States Cancer Biomarker Market Size, Share
ü Segmental Analysis – By Profiling Technology (Immunoassay,
Omics Technology, Cytogenetic Technology, Imaging Technology &
Bioinformatics), By Application (Drug Discovery and Development, Diagnosis, Prognostic,
Risk Assessment & Others), By End User (Contract Research Organizations
(CROs) and Drug Manufacturers & Healthcare Providers), By Cancer Type (Lung
Cancer, Breast Cancer, Colorectal Cancer & Others)
ü Policy & Regulatory Landscape
ü Changing Market Trends & Emerging Opportunities
ü Competitive Landscape & Strategic
Why You Should Buy This Report?
ü To identify the on-going trends and anticipated
growth in the next five years
ü To gain competitive knowledge of leading market
ü To avail 10% customization in the report without
any extra charges and get the research data or trends added in the report as
per the buyer’s specific needs
Questions This Study Will Answer
ü What would be the segmental
and regional growth trends in the United
States cancer biomarker market in the coming years?
ü What are the most important
growth drivers and opportunities in the market?
ü Which profiling technology is
preferred the most?
ü What strategies should market
competitors employ to gain share in mature segments of the United States cancer
ü What are the competitor
profiles in this market and how do they compete for market share?
The information contained in this report is
based upon both primary and secondary sources. Primary research included
interviews with cancer biomarker manufacturers and industry experts. Secondary
research included an exhaustive search of relevant publications like company
annual reports, financial reports and other proprietary databases.